White noise

Innosphere launches non-pharmaceutical ADHD clinical trial at top-tier research hospitals seeking pediatric patients

Retrieved on: 
Thursday, May 2, 2024
FDA, McGovern Medical School, Patient, Brain, Mayo Clinic, Hospital, Safety, MD, Doctor of Philosophy, Bentham Science Publishers, ADHD, White noise, Aggression, Attention, Psychiatry, Baylor College of Medicine, Headache, Texas Children's Hospital, Boston Children's Hospital, Clinical trial, Engineering

BERLIN, May 2, 2024 /PRNewswire/ - Innosphere Engineering Ltd (Innosphere or the Company), a medical device company developing non-pharmaceutical treatments for ADHD, is pleased to announce the launch of recruitment for a randomized, sham-controlled, double-blind clinical trial examining the safety and effectiveness of Novostim 2 transcranial Random Noise Stimulation (tRNS) on ADHD symptoms in pediatric patients (7 – 12 years).

Key Points: 
  • BERLIN, May 2, 2024 /PRNewswire/ - Innosphere Engineering Ltd (Innosphere or the Company), a medical device company developing non-pharmaceutical treatments for ADHD, is pleased to announce the launch of recruitment for a randomized, sham-controlled, double-blind clinical trial examining the safety and effectiveness of Novostim 2 transcranial Random Noise Stimulation (tRNS) on ADHD symptoms in pediatric patients (7 – 12 years).
  • 2016 data from the Centers for Disease Control and Prevention estimates 6 million children had been given diagnoses of ADHD and 62 percent were taking medication, often stimulants.
  • "Pharmaceuticals and specifically stimulants have been the standard of care in ADHD for decades, with challenging side effects well documented," says Rami Shacour, co-Founder and CEO of Innosphere.
  • "Building on our previous successful clinical trial , we are ecstatic to provide a non-medicated option for children in need and look forward to a swift and impactful trial."

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Retrieved on: 
Monday, December 18, 2023
Patient, Map, Downregulation and upregulation, KAT, Kronos, Research, SYK, CDK9, Dana–Farber Cancer Institute, CRH, Disease, Multiple myeloma, SAN, KRON, White noise, Infection, Cancer, IRF4, TRN, AML, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced an update on its pipeline. After a review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the Company has decided not to proceed to phase 2. The Company is open to further development of lanraplenib, a SYK inhibitor, with a partner.

Key Points: 
  • The Company is open to further development of lanraplenib, a SYK inhibitor, with a partner.
  • Kronos Bio also announced the designation of a new development candidate, KB-9558, which targets the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 transcription regulatory network (TRN).
  • “Kronos Bio was founded with a clear vision: to tackle the challenge of deregulated transcription, a hallmark of cancer,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
  • We look forward to continuing to work with the Kronos Bio team to bring KB-9558 to patients.”
    “We believe that KB-9558 is positively differentiated from compounds targeting other p300 domains,” said Christopher Dinsmore, Ph.D., chief scientific officer of Kronos Bio.

CANADA GOOSE PUTS THE FOCUS ON BOLD AND BRAVE WOMEN IN ALL-FEMALE SEASONAL CAMPAIGN PHOTOGRAPHED BY ANNIE LEIBOVITZ

Retrieved on: 
Thursday, September 22, 2022
Aurora, DJ, Weather, Culture, Personality, TSX, Woman, Arctic, NYSE, White noise, Nature, Industry, Leibovitz, Television, Female, Camping, Scottish Highlands, Spring, Summer, Fall, Winter... and Spring, GOOS, Native Americans, The Independent, Collection, Open, Equality, APEX, Multimedia, Experience, Interior design, Toy, Entertainment, Fur clothing, Chippewa Cree, Canada goose

She is involved with Equality Now, a non-profit focused on creating, reforming, challenging, and applying the law to establish enduring equality for women and girls everywhere.

Key Points: 
  • She is involved with Equality Now, a non-profit focused on creating, reforming, challenging, and applying the law to establish enduring equality for women and girls everywhere.
  • Canada Goose continues to bring its performance-driven approach to new products while looking to inspire the female consumer.
  • Canada Goose is inspired by relentless innovation and uncompromised craftsmanship, recognized as a leader for its Made in Canada commitment.
  • Canada Goose also owns Baffin, a Canadian designer and manufacturer of performance outdoor and industrial footwear.

STXfilms: Adam Driver, Penélope Cruz and Shailene Woodley Join Michael Mann’s “Ferrari”

Retrieved on: 
Wednesday, February 9, 2022
Sports, Other Entertainment, Film & Motion Pictures, Celebrity, Consumer, Motor Sports, Other Consumer, Entertainment, Don, Bankruptcy, Emmy Awards, Last Duel, Industry, Business, BlacKkKlansman, Irish people, Aviator, ErosSTX, Public Enemy, Ford Motor Company, Fury, CAA, Woman, BAFTA, Academy, Ferrari, Gentleman, HBO Max, White noise, Machine, House, Contractor, Black Mass, Star Wars, Brock, Emilia-Romagna, The Jericho Mile, The Gift, Mille Miglia, STX, Official Competition, STX Entertainment, Marriage Story, Life, Universal Pictures Home Entertainment, Jericho, List of common film awards categories, Upside, Insider, Motion, Thirteen Lives, Best Supporting Actress, Hyperion, Gift, Film, Heat, Collateral, Sony, Showtime, Parallel Mothers

Academy Award-nominee Michael Mann (Collateral, Public Enemies, Heat) has cast Academy Award nominee Adam Driver (Marriage Story, Star Wars) and Academy Award winner Penlope Cruz (Parallel Mothers, Vicky Cristina Barcelona) as Enzo and Laura Ferrari and Shailene Woodley (Big Little Lies, The Descendants) as Lina Lardi in his highly anticipated film Ferrari.

Key Points: 
  • Academy Award-nominee Michael Mann (Collateral, Public Enemies, Heat) has cast Academy Award nominee Adam Driver (Marriage Story, Star Wars) and Academy Award winner Penlope Cruz (Parallel Mothers, Vicky Cristina Barcelona) as Enzo and Laura Ferrari and Shailene Woodley (Big Little Lies, The Descendants) as Lina Lardi in his highly anticipated film Ferrari.
  • All the dramatic forces of his life - as volatile as the red race cars he builds - are in collision.
  • Michael Mann has said, Being able to have these wonderfully talented artists, actors Adam Driver, Penlope Cruz and Shailene Woodley, bring to life these unique characters on location in Modena and the Emilia-Romagna is a vision fulfilled.
  • Adam Fogelson has added Ferrari is so much more than a story about a man and his machine.

Floowood Release Double-Album, Inferno: Descent & Ascent, Released On All Streaming Platforms

Retrieved on: 
Wednesday, November 17, 2021
Singing, DMT, Anthem, Compassion, Gold, Sound, Human, Intimate relationship, White noise, EDM, Book, Liberation, Descent, Imagination, Anger, Post Malone, Solution, Multimedia, Life, Generosity, YouTube, Music

On November 11, 2021, Floowood gave us the two-headed monstrosity, Inferno: Descent & Ascent.

Key Points: 
  • On November 11, 2021, Floowood gave us the two-headed monstrosity, Inferno: Descent & Ascent.
  • Floowood is a published author, film producer, and recording artist who has gained notoriety through his writing, visuals, and musical performances.
  • Though one might not necessarily consider Floowood traditional Hip Hop, songs from Descent like "White Noise" and "Lil Sheep"... Show the world that Floowood does in fact, have bars.
  • All things Floowood can be found at floowood.com, including "The Book of Inferno" and the hottest Inferno merchandise.

Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results

Retrieved on: 
Tuesday, November 9, 2021
Intelligence, Cancer, American Association, Therapy, Security (finance), American Association for Cancer Research, Food, D, COVID-19, Target, Tempus, Projection, Cell, Risk, Safety, PK, Acceleration, SAN, Factor X, Acute myeloid leukemia, Prostate, Trial of the century, Research, Forward-looking statement, White noise, Association, Â, Conference, U.S. Securities and Exchange Commission, GLOBE, KRON, Poster, Patient, Private Securities Litigation Reform Act, PD, Drug discovery, TRN, Program, Induction chemotherapy, AR, CRPC, SEC, CDK9, Investment, Prostate cancer, MRD, SYK, AACR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LinkedIn, MYC, Precision medicine, Nasdaq, IND, Pharmaceutical industry, Cryptocurrency, Medical imaging

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter financial results.

Key Points: 
  • The companys existing development candidate, KB-0742, targets CDK9 and is being evaluated in a Phase 1/2 clinical study.
  • Additionally, Kronos Bio yesterday announced a multi-year collaboration with Tempus, a leader in artificial intelligence and precision medicine.
  • Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.